Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

Weitere Versionen anzeigen (1)

Background For women with oestrogen receptor (ER)-positive early breast cancer, treatment with tamoxifen for 5 years substantially reduces the breast cancer mortality rate throughout the first 15 years after diagnosis. We aimed to assess the further effects of continuing tamoxifen to 10 years instea...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser: Davies, C, Pan, H, Gray, R, Collins, R, Delmestri, A, Wang, Y, Peto, R, Godwin, J, Arriagada, R, Raina, V, Abraham, M, Medeiros Alencar, V, Badran, A, Khaled, H, Bonfill, X, Tort, S, Urrútia, G, Bradbury, J, Davis, SR, Clarke, M, Forbes, J, Haddad, P, Hou, M, Inbar, M, Kielanowska, J
Format: Journal article
Veröffentlicht: 2013

Ähnliche Einträge